ProCE Banner Activity


The Expanding Role of Antibody–Drug Conjugates: A Look at Vedotin

Text Module

Antibody–drug conjugates (ADC) are a newer class of agents in both hematologic and solid tumor malignancies that are designed to allow targeted delivery of potent cytotoxic chemotherapy directly to cancer cells. Of the 12 currently approved ADCs, 4 contain the cytotoxic payload vedotin (monomethyl auristatin E). Although ADCs containing vedotin share some similar toxicities, they are also each associated with unique toxicities that warrant close monitoring and supportive care strategies. This activity details the structure and mechanism of action of ADCs, with an in-depth focus on those containing vedotin—brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin, and tisotumab vedotin—with clinical pearls on using these medications in practice provided by an expert.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: September 09, 2022

Expiration: September 08, 2023

No longer available for credit.



Kirollos Hanna

Kirollos Hanna, PharmD, BCPS, BCOP

Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota
Oncology Pharmacy Manager
M Health Fairview
Maple Grove, Minnesota


This activity is supported by an educational grant from Astellas and Seagen Inc.

Provided by

ProCE Banner



Seagen Inc.

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the mechanism of action of ADCs

  • Appraise patient tumor and disease characteristics to determine the suitability of treatment with vedotin-containing ADCs

  • Formulate a monitoring and treatment plan for the AEs associated with vedotin-containing ADCs in cancer patients


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Kirollos Hanna, PharmD, BCPS, BCOP: consultant/advisor/speaker: BeiGene, Bristol Myers Squibb, Exelixis, SeaGen.

Kristi Kay Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, CTI, Gilead, Lilly, Morphosys, Pfizer, Regeneron, Sanofi.

None of the members of the Planning Committee or staff at PCE and PACE have any relevant financial relationships to disclose, except Kristi Kay Orbaugh, MSN, NP, AOCNP as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.

Release date: September 9, 2022
Expiration date: September 8, 2023


eNewsletter with interactive benchmarking and audio commentary


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education (PACE), Practicing Clinicians Exchange, or any educational supporter.


Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Kristi Kay Orbaugh, MSN, NP, AOCNP, Community Hospital Oncology Physicians, Indianapolis, Indiana
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until September 8, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.